Neuroprolotherapy and Perineural Dextrose Injections: What They Are and What the Evidence Shows

Neuroprolotherapy, Perineural Injection Therapy, and perineural dextrose injections. These terms are still relatively unfamiliar to patients and can easily cause confusion, particularly because some of these procedures involve the use of dextrose, the same substance also used in prolotherapy.
Are prolotherapy and neuroprolotherapy the same thing?
No.
Using the same substance does not necessarily mean sharing the same anatomical target, concentration, technique, indications or therapeutic rationale.
This distinction is essential when considering what we currently know about perineural dextrose injections — and, just as importantly, what the scientific evidence does not yet allow us to claim.
In brief: prolotherapy has been studied primarily in the context of musculoskeletal structures, whereas perineural dextrose therapy focuses on peripheral nerves and the tissues surrounding them.
Why do we use the term “neuroprolotherapy”?
The term neuroprolotherapy has been used to describe injection techniques targeting peripheral nerves and the surrounding tissues.
The scientific literature also uses the term Perineural Injection Therapy (PIT).
“Perineural” literally means around a nerve.
It does not mean injecting a substance into the nerve itself.
One of the approaches studied involves the use of 5% dextrose, commonly referred to as D5W in the international literature.
It is precisely the use of dextrose that can lead to confusion with prolotherapy.
Prolotherapy and neuroprolotherapy: what is the difference?
The simplest way to understand the distinction is to consider the anatomical target.
Prolotherapy
Prolotherapy is used primarily in the musculoskeletal setting.
Depending on the condition and protocol, treatment may target tendons, entheses, ligaments, joints or other musculoskeletal structures considered clinically relevant.
Dextrose is used at concentrations that may vary according to the protocols described in the literature.
For a general overview of the technique, see Prolotherapy: What It Is, Whether It Works and When It May Be Appropriate.
For further information on the conditions in which prolotherapy has been used and studied, see Clinical Indications for Prolotherapy.
Neuroprolotherapy and perineural therapy
In neuroprolotherapy, the focus shifts towards the peripheral nerve and the tissues surrounding it.
One of the most extensively studied solutions is 5% dextrose in water (D5W).
It would therefore be inaccurate to describe neuroprolotherapy simply as:
“prolotherapy applied to nerves”.
Dextrose may be a common element, but the target, concentration, technique and clinical indication may differ.
What is 5% dextrose?
Dextrose is D-glucose.
A 5% solution contains 5 grams of dextrose per 100 mL of solution.
D5W is frequently used in studies investigating perineural injections.
This distinction matters because musculoskeletal prolotherapy studies also investigate protocols using different dextrose concentrations.
It is therefore of limited value to ask simply:
“Does glucose work for pain?”
A more scientifically meaningful question is:
at what concentration, at which anatomical site, using which technique, for which clinical condition and compared with which treatment?
This is the same principle discussed in our article on prolotherapy and tendinopathies.
Why use dextrose around a nerve?
This is one of the most scientifically interesting questions in this field and, at the same time, one that requires considerable caution.
Several mechanisms have been proposed through which dextrose might influence pain perception and the biological environment surrounding a nerve.
However, the mechanisms through which perineural dextrose may produce a clinical benefit have not yet been fully established.
This is an important distinction.
A favourable clinical outcome observed in a study does not automatically demonstrate the biological mechanism responsible for that outcome.
Does neuroprolotherapy regenerate nerves?
No — at least, this cannot currently be claimed on the basis of the available evidence.
Statements such as:
“it regenerates the nerve”;
“it repairs a damaged nerve”;
“it rebuilds the nerve”
go beyond what clinical studies have demonstrated.
Studies of perineural injections primarily assess outcomes such as pain, function and symptoms and, in some cases, ultrasound or electrophysiological parameters.
Improvements in these outcomes do not automatically constitute evidence of anatomical nerve regeneration.
The same distinction applies to prolotherapy more broadly: a clinical improvement and evidence of tissue regeneration are two different claims.
Where is the evidence currently most promising?
A substantial part of the literature concerns certain peripheral entrapment neuropathies.
These are conditions in which a peripheral nerve may be subjected to compression or other alterations along its course.
Conditions that have been investigated include:
carpal tunnel syndrome;
ulnar neuropathy;
meralgia paraesthetica.
This does not mean that all these conditions should be treated with dextrose.
It simply means that clinical studies are available in these areas and can be critically evaluated.
Carpal tunnel syndrome: one of the most extensively studied areas
Carpal tunnel syndrome is one of the most extensively studied conditions in relation to perineural D5W injections.
A systematic review and meta-analysis published in 2025 evaluated 13 studies involving a total of 754 patients with upper-limb compression neuropathies.
The authors reported favourable results for dextrose in relation to pain and function in several comparisons.
However, their conclusions also contained an equally important qualification:
further high-quality studies are needed to confirm these findings and to better define injection doses and protocols.
The full study is available on PubMed – A systematic review and meta-analysis of the effectiveness of perineural dextrose injection in peripheral compression neuropathies of the upper limbs.
Dextrose or corticosteroid for carpal tunnel syndrome?
In 2026, a randomised, double-blind clinical trial directly compared D5W with corticosteroid in mild-to-moderate carpal tunnel syndrome.
The study included 57 patients, representing a total of 114 hands.
Each participant received D5W in one hand and corticosteroid in the other, with follow-up extending to 12 months.
Both treatments resulted in clinical improvement.
The greatest benefit was observed primarily during the first three months and, overall, the outcomes of the two treatments were comparable.
At 12 months, clinically meaningful improvement in symptom severity was observed in 29% of hands treated with D5W and 25% of those treated with corticosteroid.
The authors concluded that D5W may represent a potential non-steroidal option for perineural treatment in mild-to-moderate carpal tunnel syndrome.
The study is available on PubMed – Efficacy of Perineural Dextrose Versus Corticosteroid Injection for Carpal Tunnel Syndrome.
This is an interesting finding.
It does not, however, mean that dextrose is “better than corticosteroids” for every neuropathy.
It means that in this particular population, using this technique and protocol, the treatments produced comparable outcomes.
Meralgia paraesthetica
Another condition that has been investigated is meralgia paraesthetica.
This condition affects the lateral femoral cutaneous nerve and may cause burning pain, tingling, altered sensation and pain over the lateral aspect of the thigh.
A randomised, double-blind study compared perineural treatment with 5% dextrose and corticosteroid.
Both groups showed improvement, while the D5W group demonstrated better results for some outcomes at later follow-up assessments.
The study is available on PubMed – Randomized Double-blind Trial of 5% Dextrose Versus Corticosteroid Treatment for Meralgia Paresthetica.
Again, these findings must be interpreted within their specific clinical context.
Results obtained for one condition using a particular protocol cannot automatically be extrapolated to all forms of peripheral nerve pain.
Ulnar neuropathy
Ulnar neuropathy at the elbow has also been investigated.
A randomised controlled trial evaluated ultrasound-guided perineural injections of 5% dextrose and reported improvements in pain, disability and certain electrophysiological and ultrasound parameters compared with the control group.
The study is available on PubMed – Effect of Perineural Dextrose Injection on Ulnar Neuropathy at the Elbow.
Once again, these findings support scientific interest in D5W for certain entrapment neuropathies, rather than a universal indication for neuroprolotherapy.
What about other types of pain?
Here, the evidence becomes more fragmented.
Studies, clinical series and exploratory investigations have been published in a range of conditions, but the quantity and quality of the evidence are not consistent.
For example, a retrospective study evaluated perineural injections with buffered 5% dextrose in patients with neuropathic pain.
The findings suggest potential benefits, but the retrospective design means that the study cannot be given the same evidential weight as a randomised clinical trial.
The study is available through PubMed Central – The effect of perineural injection therapy on neuropathic pain.
This highlights an essential principle when interpreting the literature:
not all studies provide the same level of evidence.
A case report can generate a hypothesis.
A case series may identify a signal.
A randomised trial allows more robust comparisons.
A systematic review may help us understand the overall evidence, but its conclusions depend on the quality and heterogeneity of the studies it includes.
For this reason, Proloterapia.eu includes a dedicated section on the Scientific Literature.
Does burning or electric-shock-like pain mean that neuroprolotherapy is needed?
No.
Burning, electric-shock-like sensations, tingling, numbness or hypersensitivity may be compatible with involvement of a neural structure.
But a symptom is not, in itself, an indication for treatment.
Pain can arise from different conditions, and the first question should therefore be:
what is causing the pain?
Only then does it become appropriate to consider whether a particular procedure may have a role.
This is particularly important because someone searching for information about neuroprolotherapy may have encountered the term while initially looking for an explanation for a symptom.
To understand the clinical pathway from symptoms to assessment, see the related article by physiatrist Giuseppe Ridulfo:
Burning, stabbing or radiating nerve pain: what could be causing it?
EDITORIAL NOTE: Insert the definitive link to the Giuseppe Ridulfo article once the English version has been published.
What can we currently say about neuroprolotherapy?
We can say that perineural injections with 5% dextrose are being investigated scientifically and that clinical studies, including randomised trials, have been conducted in certain peripheral neuropathies.
The evidence is particularly interesting in the field of entrapment neuropathies, with a larger body of research available for carpal tunnel syndrome.
At the same time:
protocols are not completely standardised;
the mechanism of action has not been definitively established;
the quality of the evidence varies according to the condition;
results obtained in one neuropathy cannot automatically be extrapolated to all forms of neuropathic pain;
there is no evidence that the treatment universally “regenerates” nerves.
This may be a less spectacular description of neuroprolotherapy.
But it is also closer to the current state of the evidence.
Prolotherapy and neuroprolotherapy: the same substance, different scientific questions
Dextrose is a common element in different procedures.
This makes the research particularly interesting, but it also creates a risk of grouping together interventions that are not equivalent.
In prolotherapy, dextrose may be used at different concentrations and administered to musculoskeletal structures.
In perineural therapy, 5% dextrose around a peripheral nerve is frequently investigated.
For this reason, Proloterapia.eu does not consider “dextrose injection” to be a sufficiently precise category for interpreting a study.
We must always ask:
What was treated?
At what concentration?
At which anatomical site?
Using which technique?
Compared with which control?
Over what period of time?
Which outcomes were measured?
Only then can we begin to understand what a study actually tells us.
Frequently Asked Questions
What is neuroprolotherapy?
Neuroprolotherapy is a term used to describe injection-based approaches targeting peripheral nerves or the tissues surrounding them. The term Perineural Injection Therapy is also used in the scientific literature.
Are neuroprolotherapy and prolotherapy the same thing?
No. Both may involve the use of dextrose, but they differ in terms of anatomical target, concentration, technique, indication and therapeutic rationale.
What is D5W?
D5W is 5% dextrose in water. It is one of the solutions most frequently investigated for perineural injections.
Which conditions has it been studied for?
The largest body of literature concerns certain peripheral entrapment neuropathies, particularly carpal tunnel syndrome. Studies have also investigated ulnar neuropathy, meralgia paraesthetica and other conditions.
Does 5% dextrose regenerate nerves?
This cannot be concluded from the currently available clinical evidence. Studies primarily report potential effects on pain, symptoms and function, while the underlying biological mechanisms remain an area of ongoing research.
Does neuroprolotherapy work for every type of neuropathic pain?
No. The evidence varies considerably according to the condition being studied. Findings in entrapment neuropathies cannot automatically be extrapolated to all forms of neuropathic pain.
Do burning and tingling mean that neuroprolotherapy is indicated?
No. These symptoms can have many different causes. An appropriate diagnosis should be established before any treatment is considered.


Comments